ARPC4 Goat Polyclonal Antibody

CAT#: TA305659

Goat Anti-ARPC4 Antibody



Need it in bulk or conjugated?
Get a free quote

CNY 5,371.00


货期*
5周

规格
    • 100 ug

Product images

经常一起买 (2)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Transient overexpression lysate of actin related protein 2/3 complex, subunit 4, 20kDa (ARPC4), transcript variant 1
    • 100 ug

CNY 3,080.00

Specifications

Product Data
Applications WB
Recommend Dilution WB: 0.01-0.03ug/ml.
Reactivity Human, Mouse
Host Goat
Clonality Polyclonal
Immunogen Peptide with sequence C-ERHNKPEVEVR, from the internal region of the protein sequence according to NP_005709.1.
Formulation 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin
Concentration lot specific
Purification Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20C. Minimize freezing and thawing.
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Gene Name actin related protein 2/3 complex subunit 4
Background This gene encodes one of seven subunits of the human Arp2/3 protein complex. The Arp2/3 protein complex has been implicated in the control of actin polymerization in cells and has been conserved through evolution. The exact role of the protein encoded by this gene, the p20 subunit, has yet to be determined. Three transcript variants encoding two distinct isoforms have been found for this gene.
Synonyms ARC20; P20-ARC
Reference Data
Protein Pathways Fc gamma R-mediated phagocytosis, Pathogenic Escherichia coli infection, Regulation of actin cytoskeleton
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...